alpha-aminopyridine has been researched along with Angioblastic Meningioma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adetchessi, T; Barlier, A; Chinot, O; Defilles, C; Dufour, H; Enjalbert, A; Figarella-Branger, D; Fuentes, S; Germanetti, AL; Graillon, T; Lisbonis, C; Metellus, P; Mohamed, A; Roche, PH | 1 |
1 other study(ies) available for alpha-aminopyridine and Angioblastic Meningioma
Article | Year |
---|---|
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cell Cycle; Cell Survival; Drug Therapy, Combination; Everolimus; Female; Humans; Imidazoles; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Morpholines; Neurofibromin 2; Octreotide; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Receptors, Somatostatin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |